Pharvaris NV (PHVS) Expected Move

Tracking the PHVS expected move helps you see how far Pharvaris NV's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Pharvaris NV's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the PHVS expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For PHVS, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The PHVS expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Pharvaris NV is unlikely to go.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States.

The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the PHVS expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Pharvaris NV expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about PHVS.